In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Cancer Research

Background:

• MicroRNA (miRNA) dysregulation is implicated in cancer development.
• The miR-200 family, including miR-200c and miR-141, is a key target for cancer therapy.
• Equilibrating miRNA levels aims to prevent metastatic colonization and reduce side effects.

Purpose of the Study:

• To characterize chitosan nanoplexes for miR-200c and miR-141 delivery.
• To optimize miRNA expression levels in breast cancer cells through dose studies.
• To evaluate the efficacy of chitosan nanoplexes as a miRNA delivery system.

Main Methods:

• Chitosan nanoplexes encapsulating miR-200c and miR-141 were formulated and characterized.
• Nanoplex size, surface charge (zeta potential), and miRNA protection against degradation were assessed.
• In vitro cellular uptake studies were performed, and optimal doses for specific breast cancer cell lines were determined.

Main Results:

• Chitosan nanoplexes showed sizes ranging from 294-380 nm with positive zeta potential (+12 to +26 mV).
• Nanoplexes protected miRNA from degradation for 72 hours in serum-containing medium.
• Optimized doses for miR-200c and miR-141 were established for MCF-7, MDA-MB-231, and MDA-MB-435 cell lines.

Conclusions:

• Chitosan nanoplexes represent an efficient formulation and transfection system for miR-200c and miR-141.
• Determining optimal doses is critical for achieving effective miRNA-based cancer treatments.
• This approach holds promise for targeted cancer therapy by modulating miRNA expression.